Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy

• Published in: High blood pressure & cardiovascular prevention Vol. 25; no. 2; pp. 209 - 218
• Main Authors: Iannaccone, Andrea, Bruno, G., Ravera, A., Gay, F., Salvini, M., Bringhen, S., Sabia, L., Avenatti, E., Veglio, F., Milan, A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2018; Springer Nature B.V
• Subjects: Aged; Antineoplastic Agents - adverse effects; Asymptomatic Diseases; Blood pressure; Bortezomib - adverse effects; Cardiology; Cardiotoxicity; Cardiovascular disease; Case-Control Studies; Diabetes; Echocardiography, Doppler; Family medical history; Female; Heart rate; Humans; Hypertension; Male; Medicine; Medicine & Public Health; Middle Aged; Morphology; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Multiple Myeloma - enzymology; Oligopeptides - adverse effects; Original Article; Patients; Pharmacotherapy; Proteasome Endopeptidase Complex - drug effects; Proteasome Endopeptidase Complex - metabolism; Proteasome Inhibitors - adverse effects; Risk Factors; Software; Statistical analysis; Toxicity; Treatment Outcome; Ventricular Dysfunction, Left - chemically induced; Ventricular Dysfunction, Left - diagnostic imaging; Ventricular Dysfunction, Left - physiopathology; Ventricular Function, Left - drug effects; United States > US; Carfilzomib; Global longitudinal strain; Cardiovascular toxicity; Proteasome inhibitors; Multiple myeloma

Introduction Recently new treatment options have substantially increased survival for patients with relapsed and/or refractory multiple myeloma (RRMM). Among these, proteasome inhibitors (PI), such as bortezomib and carfilzomib, offer high response rate and prolonged survival. These agents are gener...